AU2001277570A1 - Oral pharmaceutical composition with controlled release and prolonged absorption - Google Patents
Oral pharmaceutical composition with controlled release and prolonged absorptionInfo
- Publication number
- AU2001277570A1 AU2001277570A1 AU2001277570A AU7757001A AU2001277570A1 AU 2001277570 A1 AU2001277570 A1 AU 2001277570A1 AU 2001277570 A AU2001277570 A AU 2001277570A AU 7757001 A AU7757001 A AU 7757001A AU 2001277570 A1 AU2001277570 A1 AU 2001277570A1
- Authority
- AU
- Australia
- Prior art keywords
- active principle
- controlled release
- forming
- polymer
- microcapsules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000013270 controlled release Methods 0.000 title abstract 3
- 230000002035 prolonged effect Effects 0.000 title abstract 2
- 238000010521 absorption reaction Methods 0.000 title 1
- 239000008203 oral pharmaceutical composition Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- 229920001477 hydrophilic polymer Polymers 0.000 abstract 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- 239000003094 microcapsule Substances 0.000 abstract 2
- 229920000642 polymer Polymers 0.000 abstract 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 abstract 1
- 239000001856 Ethyl cellulose Substances 0.000 abstract 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 229940072056 alginate Drugs 0.000 abstract 1
- 235000010443 alginic acid Nutrition 0.000 abstract 1
- 229920000615 alginic acid Polymers 0.000 abstract 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 abstract 1
- 239000001639 calcium acetate Substances 0.000 abstract 1
- 229960005147 calcium acetate Drugs 0.000 abstract 1
- 235000011092 calcium acetate Nutrition 0.000 abstract 1
- 239000000969 carrier Substances 0.000 abstract 1
- 239000004359 castor oil Substances 0.000 abstract 1
- 235000019438 castor oil Nutrition 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 239000002131 composite material Substances 0.000 abstract 1
- 230000003111 delayed effect Effects 0.000 abstract 1
- 235000019325 ethyl cellulose Nutrition 0.000 abstract 1
- 229920001249 ethyl cellulose Polymers 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 1
- 229960003105 metformin Drugs 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 235000016709 nutrition Nutrition 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
The invention concerns a galenic system with prolonged/controlled release of the medicinal and/or nutritional active principle, for oral administration. The aim is to provide a system enabling to obtain with one single tolerable and acceptable dose of active principle, efficient therapeutic protection over 24 hours (increasing the bioabsorption time without affecting bioavailability). To achieve this, the invention provides a composition comprising two controlled release systems associated in series, namely: individualised coated particles (microcapsules) of active principle forming an internal phase, the coating comprising a film-forming polymer P1 (ethylcellulose), a nitrogenous polymer (polyvinylpyrrolidone), a softener (castor oil) and a lubricant (magnesium stearate), and an external phase of functional carriers: polyelectrolytic hydrophilic polymer: (alginate), neutral hydrophilic polymer (hydroxypropylmethylcellulose) and a gelling additive (calcium acetate), said composition spontaneously forming in the presence of water, a cohesive and stable composite macroscopic solid, wherein the external continuous phase is a gelled matrix including the active principle microcapsules. The invention is useful for delayed oral galenic formulation of metformin.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0009047 | 2000-07-11 | ||
| FR0009047A FR2811571B1 (en) | 2000-07-11 | 2000-07-11 | ORAL PHARMACEUTICAL COMPOSITION FOR CONTROLLED RELEASE AND SUSTAINED ABSORPTION OF AN ACTIVE INGREDIENT |
| PCT/FR2001/002224 WO2002003964A1 (en) | 2000-07-11 | 2001-07-10 | Oral pharmaceutical composition with controlled release and prolonged absorption |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001277570A1 true AU2001277570A1 (en) | 2002-01-21 |
Family
ID=8852353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001277570A Abandoned AU2001277570A1 (en) | 2000-07-11 | 2001-07-10 | Oral pharmaceutical composition with controlled release and prolonged absorption |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20040022849A1 (en) |
| EP (1) | EP1299090B1 (en) |
| JP (1) | JP2004502723A (en) |
| AT (1) | ATE319431T1 (en) |
| AU (1) | AU2001277570A1 (en) |
| BR (1) | BR0112532A (en) |
| CA (1) | CA2415378C (en) |
| DE (1) | DE60117801T2 (en) |
| ES (1) | ES2260253T3 (en) |
| FR (1) | FR2811571B1 (en) |
| IL (1) | IL153086A0 (en) |
| WO (1) | WO2002003964A1 (en) |
| ZA (1) | ZA200209525B (en) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2816840B1 (en) * | 2000-11-17 | 2004-04-09 | Flamel Tech Sa | MEDICINE BASED ON SUSTAINED RELEASE ANTI-HYPERCLYCEMIA MICROCAPSULES AND METHOD FOR PREPARING THE SAME |
| JP3834215B2 (en) | 2001-09-07 | 2006-10-18 | アグリテクノ矢崎株式会社 | Gel coated seeds |
| US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
| FR2830447B1 (en) * | 2001-10-09 | 2004-04-16 | Flamel Tech Sa | MICROPARTICULAR ORAL GALENIC FORM FOR DELAYED AND CONTROLLED RELEASE OF PHARMACEUTICAL ACTIVE INGREDIENTS |
| MXPA04009979A (en) | 2002-04-09 | 2004-12-13 | Flamel Tech Sa | Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillin. |
| CN100553625C (en) | 2002-04-09 | 2009-10-28 | 弗拉梅技术公司 | Active ingredient microencapsulated oral suspension |
| US7670623B2 (en) * | 2002-05-31 | 2010-03-02 | Materials Modification, Inc. | Hemostatic composition |
| AU2002356419A1 (en) | 2002-06-17 | 2003-12-31 | Themis Laboratories Private Limited | Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them |
| US8268352B2 (en) * | 2002-08-05 | 2012-09-18 | Torrent Pharmaceuticals Limited | Modified release composition for highly soluble drugs |
| US8216609B2 (en) * | 2002-08-05 | 2012-07-10 | Torrent Pharmaceuticals Limited | Modified release composition of highly soluble drugs |
| US7985422B2 (en) | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| US7560160B2 (en) * | 2002-11-25 | 2009-07-14 | Materials Modification, Inc. | Multifunctional particulate material, fluid, and composition |
| US20040265372A1 (en) | 2003-06-27 | 2004-12-30 | David Wynn | Soft tablet containing high molecular weight cellulosics |
| US7448389B1 (en) | 2003-10-10 | 2008-11-11 | Materials Modification, Inc. | Method and kit for inducing hypoxia in tumors through the use of a magnetic fluid |
| WO2005065639A2 (en) * | 2003-11-21 | 2005-07-21 | Torrent Pharmaceuticals Limited | Novel pharmaceutical compositions |
| US20070219131A1 (en) * | 2004-04-15 | 2007-09-20 | Ben-Sasson Shmuel A | Compositions capable of facilitating penetration across a biological barrier |
| KR20070044805A (en) * | 2004-04-15 | 2007-04-30 | 키아스마, 인코포레이티드 | Compositions That Can Promote Biological Barrier Permeation |
| FR2889810A1 (en) * | 2005-05-24 | 2007-02-23 | Flamel Technologies Sa | ORAL MEDICINAL FORM, MICROPARTICULAR, ANTI-MEASUREMENT |
| DE102005006539A1 (en) * | 2005-02-11 | 2006-08-24 | Merck Patent Gmbh | Biguanide-containing compositions |
| WO2006133733A1 (en) | 2005-06-13 | 2006-12-21 | Flamel Technologies | Oral dosage form comprising an antimisuse system |
| FR2891459B1 (en) * | 2005-09-30 | 2007-12-28 | Flamel Technologies Sa | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE INGREDIENT AND ORAL GALENIC FORM COMPRISING THE SAME |
| US8652529B2 (en) | 2005-11-10 | 2014-02-18 | Flamel Technologies | Anti-misuse microparticulate oral pharmaceutical form |
| FR2892937B1 (en) * | 2005-11-10 | 2013-04-05 | Flamel Tech Sa | MICROPARTICULAR ORAL PHARMACEUTICAL FORM ANTI-MEASURING |
| US7811604B1 (en) | 2005-11-14 | 2010-10-12 | Barr Laboratories, Inc. | Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same |
| AU2007205996A1 (en) * | 2006-01-10 | 2007-07-26 | Pipex, Inc. | Pharmaceutical compositions and methods to achieve and maintain a targeted and stable copper status and prevent and treat copper-related central nervous system diseases |
| US20070264346A1 (en) * | 2006-02-16 | 2007-11-15 | Flamel Technologies | Multimicroparticulate pharmaceutical forms for oral administration |
| US9023400B2 (en) * | 2006-05-24 | 2015-05-05 | Flamel Technologies | Prolonged-release multimicroparticulate oral pharmaceutical form |
| JP4741991B2 (en) | 2006-07-14 | 2011-08-10 | 株式会社日立製作所 | Serializer / deserializer transfer device |
| US20100105627A1 (en) | 2008-09-17 | 2010-04-29 | Paul Salama | Pharmaceutical compositions and related methods of delivery |
| JP2013515783A (en) * | 2009-12-29 | 2013-05-09 | インパックス ラボラトリーズ，インコーポレーテッド | Gastric retention type solid oral dosage form using swellable hydrophilic polymer |
| CN103037870B (en) | 2010-05-12 | 2016-05-25 | 斯派克托姆制药公司 | Basic carbonate lanthanum, carbonic acid gas lanthanum and manufacture method and purposes |
| PL2872121T3 (en) | 2012-07-12 | 2019-02-28 | SpecGx LLC | Extended release, abuse deterrent pharmaceutical compositions |
| US10842802B2 (en) * | 2013-03-15 | 2020-11-24 | Medicis Pharmaceutical Corporation | Controlled release pharmaceutical dosage forms |
| US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
| LT3253401T (en) | 2015-02-03 | 2025-07-10 | Amryt Endo, Inc. | Treating acromegaly with oral octreotide |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (en) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | FORMULATIONS OF GAMMA-MODIFIED RELEASE HYDROXIBUTIRATE WITH IMPROVED PHARMACOCINETICS |
| EP3930702A1 (en) | 2019-03-01 | 2022-01-05 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| CN110354090B (en) * | 2019-07-29 | 2021-10-01 | 石药集团欧意药业有限公司 | Metformin hydrochloride sustained release tablet and preparation method thereof |
| CN111202718A (en) * | 2020-02-25 | 2020-05-29 | 北京鑫开元医药科技有限公司 | Ranitidine hydrochloride capsule and preparation method thereof |
| US11141457B1 (en) | 2020-12-28 | 2021-10-12 | Amryt Endo, Inc. | Oral octreotide therapy and contraceptive methods |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6248618A (en) * | 1985-08-27 | 1987-03-03 | Zeria Shinyaku Kogyo Kk | Slow-releasing drug preparation and production thereof |
| US5268182A (en) * | 1988-06-24 | 1993-12-07 | Abbott Laboratories | Sustained-release drug dosage units of terazosin |
| CA2007181C (en) | 1989-01-06 | 1998-11-24 | Angelo Mario Morella | Sustained release pharmaceutical composition |
| IT1250421B (en) | 1991-05-30 | 1995-04-07 | Recordati Chem Pharm | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION WITH BIO-ADHESIVE PROPERTIES. |
| FR2704146B1 (en) * | 1993-04-19 | 1995-07-13 | Cripdom | Microcapsules of acetylsalicylic acid with controlled release. |
| JP2977907B2 (en) * | 1994-05-06 | 1999-11-15 | ファイザー・インコーポレーテッド | Controlled release dosage form of azithromycin |
| DE4432757A1 (en) | 1994-09-14 | 1996-03-21 | Boehringer Mannheim Gmbh | Pharmaceutical preparation containing metformin and process for its preparation |
| FR2725623A1 (en) * | 1994-10-18 | 1996-04-19 | Flamel Tech Sa | MEDICINAL AND / OR NUTRITION MICROCAPSULES FOR PER OS ADMINISTRATION |
| US5858398A (en) | 1994-11-03 | 1999-01-12 | Isomed Inc. | Microparticular pharmaceutical compositions |
| ID26082A (en) * | 1998-03-19 | 2000-11-23 | Briston Myers Squib Company | DWIFASA CONTROLLED REMOVAL DELIVERY SYSTEM FOR HIGH SOLUTION PHARMACY SUBSTANCES AND ITS METHODS |
| US6099859A (en) | 1998-03-20 | 2000-08-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral tablet having a unitary core |
| US5945123A (en) * | 1998-04-02 | 1999-08-31 | K-V Pharmaceutical Company | Maximizing effectiveness of substances used to improve health and well being |
| US6499158B1 (en) | 2000-10-30 | 2002-12-31 | Steris, Inc. | Surgical table top and accessory clamp used thereon |
-
2000
- 2000-07-11 FR FR0009047A patent/FR2811571B1/en not_active Expired - Fee Related
-
2001
- 2001-07-10 JP JP2002508419A patent/JP2004502723A/en active Pending
- 2001-07-10 AT AT01955397T patent/ATE319431T1/en not_active IP Right Cessation
- 2001-07-10 BR BR0112532-0A patent/BR0112532A/en not_active IP Right Cessation
- 2001-07-10 AU AU2001277570A patent/AU2001277570A1/en not_active Abandoned
- 2001-07-10 CA CA2415378A patent/CA2415378C/en not_active Expired - Fee Related
- 2001-07-10 US US10/332,463 patent/US20040022849A1/en not_active Abandoned
- 2001-07-10 EP EP01955397A patent/EP1299090B1/en not_active Expired - Lifetime
- 2001-07-10 WO PCT/FR2001/002224 patent/WO2002003964A1/en not_active Ceased
- 2001-07-10 DE DE60117801T patent/DE60117801T2/en not_active Expired - Lifetime
- 2001-07-10 IL IL15308601A patent/IL153086A0/en unknown
- 2001-07-10 ES ES01955397T patent/ES2260253T3/en not_active Expired - Lifetime
-
2002
- 2002-11-22 ZA ZA200209525A patent/ZA200209525B/en unknown
-
2007
- 2007-03-21 US US11/723,553 patent/US7879362B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1299090A1 (en) | 2003-04-09 |
| FR2811571A1 (en) | 2002-01-18 |
| US20070207214A1 (en) | 2007-09-06 |
| JP2004502723A (en) | 2004-01-29 |
| US7879362B2 (en) | 2011-02-01 |
| BR0112532A (en) | 2003-07-29 |
| DE60117801D1 (en) | 2006-05-04 |
| CA2415378A1 (en) | 2002-01-17 |
| FR2811571B1 (en) | 2002-10-11 |
| US20040022849A1 (en) | 2004-02-05 |
| CA2415378C (en) | 2010-03-16 |
| DE60117801T2 (en) | 2006-11-23 |
| IL153086A0 (en) | 2003-06-24 |
| EP1299090B1 (en) | 2006-03-08 |
| ATE319431T1 (en) | 2006-03-15 |
| ZA200209525B (en) | 2003-11-24 |
| WO2002003964A1 (en) | 2002-01-17 |
| ES2260253T3 (en) | 2006-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001277570A1 (en) | Oral pharmaceutical composition with controlled release and prolonged absorption | |
| UA29563C2 (en) | Microcapsule for prolonged release of physiologically active peptide | |
| AU4882597A (en) | Pharmaceutical preparations for the controlled release of beta-lactam antibiotics | |
| TW429154B (en) | A controlled release formulation for poorly soluble basic drugs | |
| IE970588A1 (en) | Controlled release pharmaceutical compositions containing tiagabine | |
| AU4121297A (en) | Galenic form with extended release of milnacipran | |
| AU7143796A (en) | Controlled release matrix for pharmaceuticals | |
| ATE424810T1 (en) | A DELAYED-RELEASE TABLET CONTAINING A HYDROCOLLOID AND A CELLULOSE ETHER | |
| AU2223095A (en) | Effervescent pharmaceutical formulations containing controlled release biodegradable microcapsules | |
| CA2253980A1 (en) | Locally administrable, biodegradable and sustained-release pharmaceutical composition for periodontitis and process for preparation thereof | |
| BG100933A (en) | Polymer coated tablets comprising amoxycilin and clavulanate | |
| DE69816951D1 (en) | Preparation containing cefaclor or cephalexin with a modified release matrix | |
| IL111647A (en) | Pharmaceutical compositions comprising microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles and their preparation | |
| CA2352211A1 (en) | Sustained release matrix systems for highly soluble drugs | |
| AU4903700A (en) | Chronotherapeutic diltiazem formulations and the administration thereof | |
| NZ503538A (en) | Moxifloxacin formulation characterised by the release times containing hydroxypropylmethylcellulose or polyvinylpyrrolidone as binder and ethylcellulose as film forming polymer | |
| DE69622739D1 (en) | PHARMACEUTICAL PREPARATION WITH QUICK RELEASE | |
| CA2383212A1 (en) | Controlled release oral dosage suitable for oral administration | |
| AU3071300A (en) | Multiparticulate bisoprolol formulation | |
| DE60117712D1 (en) | PHARMACEUTICAL COMPOSITION FOR THE CONTROLLED RELEASE OF BETA LACTAM ANTIBIOTICS | |
| EP0761209A3 (en) | Controlled release formulations of ranitidine | |
| CA2187153A1 (en) | Effervescent pharmaceutical formulations containing controlled release biodegradable microcapsules | |
| CA2566590A1 (en) | Cronotherapeutic diltiazem formulation and the administration thereof | |
| MY114610A (en) | Controlled drug delivery system for diltiazem. |